Open AccessPretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry
Author(s) -
Leila Hedayati Zafarghandi,
Mohammad E. Khamseh,
Milad Fooladgar,
Shahrzad Mohseni,
Mostafa Qorbani,
Nahid Hashemi Madani,
Mahboobeh Hemmatabadi,
Mohammad-Reza Mohajeri-Tehrani,
Nooshin Shirzad
Publication year - 2020
Publication title -
journal of diabetes and metabolic disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.619
H-Index - 33
ISSN - 2251-6581
DOI - 10.1007/s40200-020-00512-5
Subject(s) - medicine , acromegaly , diabetes mellitus , blood pressure , basal (medicine) , endocrinology , left ventricular hypertrophy , population , hormone , growth hormone , environmental health
Acromegaly is a rare chronic disabling disorder, in which growth hormone (GH) excess is associated with a range of clinical features and systemic complications. The present study aims to evaluate the association between pretreatment basal GH levels as well as GH levels after oral glucose tolerance test (OGTT) and cardio-metabolic comorbidities, including diabetes mellitus (DM), left ventricular hypertrophy (LVH) and hypertension (HTN) in patients with active acromegaly.